Search Results - "EOM, S. H"

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study by Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, Durie, B G M

“…Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this…”
Get full text

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma by Lee, J., Suh, C., Kang, H. J., Ryoo, B.-Y., Huh, J., Ko, Y. H., Eom, H.-S., Kim, K., Park, K., Kim, W. S.

“…The aim of the study was to determine the maximum tolerated dose (MTD) and safety of the combination of bortezomib and cyclophosphamide, doxorubicin,…”
Get full text

Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia by Yoon, J.-H., Yhim, H.-Y., Kwak, J.-Y., Ahn, J.-S., Yang, D.-H., Lee, J.-J., Kim, S.-J., Kim, J.-S., Park, S.J., Choi, C.W., Eom, H.-S., Park, S.-K., Choi, S.-Y., Kim, S.-H., Kim, D.-W., Lee, S.

“…The use of imatinib combined with chemotherapy has demonstrated improved outcome in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia…”
Get full text

Photodamage attenuation effect by a tetraprenyltoluquinol chromane meroterpenoid isolated from Sargassum muticum by Balboa, E M, Li, Y-X, Ahn, B-N, Eom, S-H, Domínguez, H, Jiménez, C, Rodríguez, J

“…A tetraprenyltoluquinol meroterpenoid with a chromane moiety, obtained as an epimeric mixture at C3, was isolated for the first time from the dichloromethane…”
Get full text

Attitudinal concordance toward uptake and disclosure of genetic testing for cancer susceptibility in patient-family member dyads by Shin, D.W., Cho, J., Roter, D.L., Kim, S.Y., Park, Ji.H., Cho, B., Eom, H.-S., Chung, J.-S., Yang, H.-K., Park, Jo.-H.

“…Decisions for cancer susceptibility genetic testing (CSGT) uptake and dissemination of results occur within the family context. A national survey was performed…”
Get full text

S200: IMPROVED OVERALL SURVIVAL WITH FIRST‐LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6‐YEAR ANALYSIS OF ECHELON‐1 by Hutchings, M., Ansell, S. M., Straus, D. J., Connors, J. M., Kim, W. S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R., Evens, A. M., Smolewski, P., Savage, K. J., Bartlett, N. L., Eom, H.‐S., Abramson, J. S., Dong, C., Campana, F., Fenton, K., Puhlmann, M., Radford, J.

Get full text

S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA by Kim, W.‐S., Yoon, D.‐H., Song, Y., Yang, H., Cao, J., Ji, D., Koh, Y., Jing, H., Eom, H.‐S., Kwak, J.‐Y., Lee, W.‐S., Lee, J.‐S., Shin, H.‐J., Jin, J., Wang, M., Li, J., Huang, X., Deng, X., Yang, Z., Zhu, J.

Get full text

Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients by Kim, M.K., Suh, C., Lee, D.H., Min, C.-K., Kim, S.J., Kim, K., Moon, J.H., Yoon, S.S., Lee, G.-W., Kang, H.J., Kim, S.-H., Choi, C.W., Eom, H.S., Kwak, J.-Y., Kim, H.J., Mun, Y.-C., Bang, S.-M., Lee, K., Shin, H.J., Lee, J.H.

“…To analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM)…”
Get full text

Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT by Yhim, H-Y, Kim, K, Kim, J S, Kang, H J, Kim, J-A, Min, C-K, Bae, S H, Park, E, Yang, D-H, Suh, C, Kim, M K, Mun, Y-C, Eom, H S, Shin, H J, Yoon, H-J, Kwon, J H, Lee, J H, Kim, Y S, Yoon, S-S, Kwak, J-Y

“…The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic…”
Get full text

Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu Cy E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma by KIM, J. G, SOHN, S. K, SUH, C, KIM, S. J, EOM, H.-S, BAE, S. H, CHAE, Y. S, YANG, D. H, LEE, J.-J, KIM, H.-J, SHIN, H. J, JUNG, J. S, KIM, W. S, KIM, D. H

“…The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous busulfan, cyclophosphamide and etoposide (i.v. Bu/Cy/E) as a…”
Get full text

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma by Kwong, Y.L., Kim, S.J., Tse, E., Oh, S.Y., Kwak, J.Y., Eom, H.S., Do, Y.R., Mun, Y.C., Lee, S.R., Shin, H.J., Suh, C., Chuang, S.S., Lee, Y.S., Lim, S.T., Izutsu, K., Suzuki, R., Relander, T., d’Amore, F., Schmitz, N., Jaccard, A., Kim, W.S.

“…In stage I/II natural killer (NK)/T-cell lymphoma, concurrent chemoradiotherapy (CCRT) had previously been shown to result in superior outcome compared with…”
Get full text

Baseline F-18 FDG PET uptake of bone marrow as a survival predictor in patients with multiple myeloma by Lee, E, Lee, H, Lee, S.J, Kim, H.J, Kim, T.-S, Sohn, J.Y, Kong, S.-Y, Eom, H.-S

Get full text

Biosynthesis, purification and characterization of silver nanoparticles using Escherichia coli by Gurunathan, Sangiliyandi, Kalishwaralal, Kalimuthu, Vaidyanathan, Ramanathan, Venkataraman, Deepak, Pandian, Sureshbabu Ram Kumar, Muniyandi, Jeyaraj, Hariharan, Nellaiah, Eom, Soo Hyun

“…The application of nanoscale materials and structures, usually ranging from 1 to 100 nanometers (nm), is an emerging area of nanoscience and nanotechnology…”
Get full text

Antiangiogenic properties of silver nanoparticles by Gurunathan, Sangiliyandi, Lee, Kyung-Jin, Kalishwaralal, Kalimuthu, Sheikpranbabu, Sardarpasha, Vaidyanathan, Ramanathan, Eom, Soo Hyun

“…Abstract Angiogenesis is an important phenomenon involved in normal growth and wound healing processes. An imbalance of the growth factors involved in this…”
Get full text

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas by Kim, S.J., Shin, D.-Y., Kim, J.S., Yoon, D.H., Lee, W.S., Lee, H., Do, Y.R., Kang, H.J., Eom, H.S., Ko, Y.H., Lee, S.H., Yoo, H.Y., Hong, M., Suh, C., Kim, W.S.

“…Everolimus, an oral mTOR inhibitor, has single-agent activity against relapsed lymphomas. Thus, we carried out a phase II study of everolimus in combination…”
Get full text

9-year follow-up bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) by Lee, E, Lee, H, Lee, J.-J, Chung, J.-S, Kim, K, Kim, H.J, Kim, H.Y, Jin, J.-Y, Do, Y.-R, Oh, S.-J, Suh, C, Seong, C.-M, Kim, C.S, Lee, D.S, Lee, J.H, Eom, H.-S

Get full text

Functional importance of polymerization and localization of calsequestrin in C. elegans by Cho, J.H, Ko, K.M, Singaruvelu, Gunasekaran, Lee, Wonhae, Kang, Gil Bu, Rho, Seong-Hwan, Park, Byung-Jae, Yu, Jae-Ran, Kagawa, Hiroaki, Eom, S.H, Kim, D.H, Ahnn, Joohong

“…Dual roles of calsequestrin (CSQ-1) being the Ca²⁺ donor and Ca²⁺ acceptor make it an excellent Ca²⁺-buffering protein within the sarcoplasmic reticulum (SR)…”
Get full text

Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells by Kalishwaralal, Kalimuthu, Banumathi, Elayappan, Pandian, SureshBabu Ram Kumar, Deepak, Venkataraman, Muniyandi, Jeyaraj, Eom, Soo Hyun, Gurunathan, Sangiliyandi

“…Angiogenesis, the growth of new blood vessels from pre-existing vasculature is of physiological and pathological importance. We have investigated the…”
Get full text

EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA by Kim, W.‐S., Yoon, D.‐H., Song, Y., Koh, Y., Cao, J., Ji, D., Yang, H., Eom, H.‐S., Jing, H., Kwak, J.‐Y., Lee, W.‐S., Lee, J.‐S., Shin, H.‐J., Jin, J., Wang, M., Li, J., Huang, X., Deng, X., Yang, Z., Zhu, J.

Get full text

PB1751: ALTERATIONS IN THE GUT MICROBIOME IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH ACUTE LEUKEMIA by Park, M., Jung, J., Jin, H.‐Y., Lee, J. A., Lee, E., Lee, H., Eom, H. S., Park, H. J.

Get full text